Development of ELISA to estimate thymosin alpha1, the N terminus of prothymosin alpha, in human tumors.
Loidi. L L; Vidal. A A; Zalvide. J B JB; Puente. J L JL; Reyes. F F; Domínguez. F F
Key Findings
- Created an ELISA using a GST‑ProT alpha fusion protein to coat plates.
- Used a rabbit polyclonal antibody that specifically detects thymosin alpha‑1.
- The ELISA is as sensitive as the older radioactive RIA method and runs faster, though it gives slightly higher readings.
Practical Outcomes
- For biohackers or self‑experimenters, this paper offers no direct advice on dosing, supplementation, or health protocols. It’s mainly relevant for labs that need to measure thymosin alpha‑1 in tumor tissue, not for personal longevity or performance optimization.
Summary
The study describes a new lab test (ELISA) that can measure a protein fragment called thymosin alpha‑1 in tumor samples. It’s a technical method for researchers or doctors, not a health tip or supplement guide for everyday use.
Abstract
We reported that tumor content of prothymosin alpha (ProT alpha) is a proliferation index of human breast tumors that might be used to identify patients at high risk for distant metastasis (Dominguez et al., Eur J Cancer 1993; 29A:893-7). In that study ProT alpha concentrations were measured by a RIA; here we present an alternative nonisotopic assay that could be used in a standard clinical laboratory. Main features of the ELISA are: (a) A recombinant fusion protein glutathione S-transferase (GST)-human ProT alpha was used to coat the microtiter plates; (b) we used a polyclonal antiserum raised in rabbits that detects thymosin alpha1, the NH2-terminal fragment of ProT alpha; (c) it is as sensitive as the RIA; (d) it is faster than the RIA. ProT alpha concentrations in various human tumors (skin, esophagus, colorectal, and breast) as assessed by ELISA were comparable with, although twofold greater than, the values previously estimated by RIA.
Study Information
pubmed
1997